Delivery Order SPE2DB20D9127-SPE2DB25FPQG3

Award Date 4/10/25
Potential Completion Date 5/1/25
Potential Value $66K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $49,224.90, covers the delivery of 4,567,115,928 units of KEYTRUDA 100 MG/4 ML VIAL 4ML, a prescription oncology medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,142.85 firm fixed-price contract is for the supply of Keytruda 100 mg/4 ml vial. The contract has an ultimate completion date of July 3, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is valued at $57,326.92 and covers the delivery of 4,567,717,128 units of Keytruda 100 mg/4 ml vial (4 ml). The contract has an ultimate completion date of April 15, 2025 and does not have a set-aside designation. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $48,131.04 contract is to provide Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $77,505.20, is for the supply of 4560048090 - KEYTRUDA 100 MG/4 ML VIAL 4ML, a specialized oncology medication. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $120,327.60 contract is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring pharmaceutical needs of military health facilities. The award is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $93,006.24 contract is for the supply of 4560498273 - Keytruda 100 mg/4 ml vial, 4 ml, with a completion date of April 24, 2023. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,563,469,465 units of the pharmaceutical product KEYTRUDA 100 MG/4 ML VIAL 4ML. The contract has a completion date of February 12, 2024 and a potential value of $80,218.40. This delivery order is part of a larger indefinite delivery contract held by DMS Pharmaceutical Group with DLA to provide various pharmaceutical and medical supplies...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $96,167.84, is to provide 4,561,258,973 units of KEYTRUDA 100 MG/4 ML VIAL 4ML, a prescription drug product, with a completion date of July 5, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $82,041.50 contract is for the delivery of 4,566,940,918 units of the pharmaceutical product Keytruda (100 mg/4 ml vial) with a period of performance through February 3, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
  • SPE2DB20D9127
    Indefinite Delivery Contract
  • SPE2DB20D9127-SPE2DB25FPQG3
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $65,633.20, is for the delivery of 4,567,903,295 units of KEYTRUDA 100 MG/4 ML VIAL 4ML, a prescription medication. The contract has a completion date of May 1, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This contract award does not have a set-aside designation.

Generated 7/17/25, 6:24 PM